NO911164L - Homolog rekombinasjon for universale donatorceller og chimere pattedyrverter. - Google Patents

Homolog rekombinasjon for universale donatorceller og chimere pattedyrverter.

Info

Publication number
NO911164L
NO911164L NO91911164A NO911164A NO911164L NO 911164 L NO911164 L NO 911164L NO 91911164 A NO91911164 A NO 91911164A NO 911164 A NO911164 A NO 911164A NO 911164 L NO911164 L NO 911164L
Authority
NO
Norway
Prior art keywords
cells
universal
hosts
chimer
donator
Prior art date
Application number
NO91911164A
Other languages
English (en)
Other versions
NO911164D0 (no
NO314458B1 (no
Inventor
Raju S Kucherlapati
Beverly H Koller
Oliver Smithies
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Publication of NO911164L publication Critical patent/NO911164L/no
Publication of NO911164D0 publication Critical patent/NO911164D0/no
Publication of NO314458B1 publication Critical patent/NO314458B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physical Deposition Of Substances That Are Components Of Semiconductor Devices (AREA)
  • Lubricants (AREA)
  • Special Wing (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
NO19911164A 1989-07-25 1991-03-22 Ikke-differensierende pattedyrcelle, fremgangsmåte for fremstilling derav,samt vev og DNA-konstruksjon NO314458B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38565189A 1989-07-25 1989-07-25
US43187289A 1989-11-06 1989-11-06
PCT/US1990/004178 WO1991001140A1 (en) 1989-07-25 1990-07-25 Homologous recombination for universal donor cells and chimeric mammalian hosts

Publications (3)

Publication Number Publication Date
NO911164L true NO911164L (no) 1991-03-22
NO911164D0 NO911164D0 (no) 1991-03-22
NO314458B1 NO314458B1 (no) 2003-03-24

Family

ID=27011096

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19911164A NO314458B1 (no) 1989-07-25 1991-03-22 Ikke-differensierende pattedyrcelle, fremgangsmåte for fremstilling derav,samt vev og DNA-konstruksjon

Country Status (9)

Country Link
US (1) US5416260A (no)
EP (2) EP0950707B1 (no)
JP (1) JPH04501510A (no)
KR (1) KR100226158B1 (no)
AT (1) ATE423195T1 (no)
AU (1) AU633958B2 (no)
DE (2) DE69033493D1 (no)
NO (1) NO314458B1 (no)
WO (1) WO1991001140A1 (no)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705732A (en) * 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US5538722A (en) * 1989-06-13 1996-07-23 Stanford University Isolation, growth, differentiation and genetic engineering of human muscle cells
US5574205A (en) * 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US6689610B1 (en) * 1989-08-22 2004-02-10 University Of Utah Research Foundation Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5877397A (en) * 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5489742A (en) * 1990-10-23 1996-02-06 Board Of Regents, The University Of Texas System Transgenic rats and animal models of inflammatory disease
WO1992009688A1 (en) * 1990-11-21 1992-06-11 Massachusetts Institute Of Technology MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION
US5686263A (en) * 1991-05-31 1997-11-11 Genentech, Inc. Method for enhancing gene expression
EP1041142A3 (en) * 1991-07-15 2007-10-24 Oklahoma Medical Research Foundation Universal donor cells
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ES2237747T3 (es) * 1991-11-14 2005-08-01 Prionics Ag Animales transgenicos no humanos que carecen de proteinas prionicas.
US20020108136A1 (en) * 1997-03-21 2002-08-08 Sri Transgenic animals produced by homologous sequence targeting
US6916654B1 (en) * 1992-06-29 2005-07-12 Oklahoma Medical Research Foundation Universal donor cells
DE4228162C1 (de) 1992-08-25 1994-01-13 Rajewsky Klaus Dr Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern
JP3741447B2 (ja) * 1992-10-23 2006-02-01 中外製薬株式会社 エンドセリン−１遺伝子の機能が欠損したマウス
WO1994016080A1 (en) * 1993-01-08 1994-07-21 Exemplar Corporation An in vitro/in vivo method for identifying anti-neoplastic drugs
US5610007A (en) * 1993-01-21 1997-03-11 Universite Laval Chimeric sheets of epithelial cells
GB9308271D0 (en) * 1993-04-21 1993-06-02 Univ Edinburgh Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
US5650550A (en) * 1993-10-01 1997-07-22 The United States Of America As Represented By The Department Of Health And Human Services Mutant mice having a deficit of functional estrogen receptors
CA2196311A1 (en) * 1994-08-19 1996-02-29 David H. Sachs Genetically engineered swine cells
CA2202549C (en) * 1994-10-14 2003-08-05 Tara Seshadri Transgenic nonhuman animal having functionally disrupted interleukin-1.beta. converting enzyme gene
EP0826034A4 (en) * 1995-04-21 2002-06-19 Cell Genesys Inc PRODUCTION OF LARGE GENOMIC DNA DELETIONS
US6884622B1 (en) 1995-04-21 2005-04-26 Abgenix, Inc Method for preparing a mammalian cell deficient in HPRT
CA2227584A1 (en) * 1995-08-04 1997-02-20 The General Hospital Corporation Transgenic swine and swine cells having human hla genes
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
GB9703550D0 (en) * 1997-02-20 1997-04-09 Ppl Therapeutics Scotland Ltd Cell mediated transgenesis
US5948653A (en) * 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
AU7137398A (en) 1997-04-16 1998-11-11 Millennium Pharmaceuticals, Inc. Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
US7316923B1 (en) 1997-09-26 2008-01-08 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
US6897066B1 (en) 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
US6194633B1 (en) 1998-01-26 2001-02-27 University Of Iowa Research Foundation Non-human animal having a functionally disrupted SLP-76 gene
WO1999038954A1 (en) 1998-02-02 1999-08-05 Johns Hopkins University School Of Medicine A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
WO1999055838A1 (en) * 1998-04-24 1999-11-04 University Of Nebraska Board Of Regents Compositions and methods for the characterization and transplantation of mammalian retinal stem cells
US6733991B1 (en) 1998-05-08 2004-05-11 Osi Pharmaceuticals, Inc. AGS proteins and nucleic acid molecules and uses therefor
US6746852B1 (en) 1998-05-08 2004-06-08 Osi Pharmaceuticals, Inc. AGS proteins and nucleic acid molecules and uses thereof
US7531715B1 (en) 1999-01-13 2009-05-12 Ppl Therapeutics (Scotland) Double nuclear transfer method and results thereof
ATE307830T1 (de) * 1999-02-05 2005-11-15 Therapeutic Human Polyclonals Aus nicht-menschlichen transgenen tieren gewonnene menschliche polyklonale antikörper
US7485293B1 (en) 1999-02-18 2009-02-03 Faustman Denise L Method for inhibiting transplant rejection
EP1154686B1 (en) * 1999-02-18 2007-10-17 FAUSTMAN, Denise L. Method for inhibiting transplant rejection
EP2301947A3 (en) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
AU2001287000A1 (en) 2000-09-01 2002-03-13 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
IL155952A0 (en) 2000-11-28 2003-12-23 Wyeth Corp Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
MXPA03004637A (es) 2000-11-28 2003-09-05 Wyeth Corp Analisis de expresion de acidos nucleicos y polipeptidos kiaa utiles en diagnostico y tratamiento de cancer de prostata.
CN1487996B (zh) * 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
EP2305795B1 (en) 2000-12-06 2019-07-03 Celularity, Inc. Method of collecting placental stem cells
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP2316918B1 (en) 2001-02-14 2015-07-01 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
ES2432493T3 (es) 2001-02-14 2013-12-03 Anthrogenesis Corporation Placenta de mamífero post-parto, su uso y células madre de la misma
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
CA2440676A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transgenic animals expressing antibodies specific for genes of interest and uses thereof
EP2388590A1 (en) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, a receptor for B7-4, and uses thereof
WO2002083855A2 (en) 2001-04-16 2002-10-24 Wyeth Holdings Corporation Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US7476536B2 (en) 2001-05-11 2009-01-13 Kirin Pharma Kabushiki Kaisha Artificial human chromosome containing human antibody a light chain gene
EP1404842A2 (en) * 2001-06-29 2004-04-07 Novartis AG Perv screening method and use thereof
EP1575916B1 (en) 2001-08-31 2013-05-22 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
CA2466415C (en) 2001-11-09 2020-01-21 Dana-Farber Cancer Institute, Inc. Pgc-1.beta., a novel pgc-1 homologue and uses therefor
EP2292091A1 (en) 2002-02-13 2011-03-09 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
US7153685B2 (en) 2002-03-11 2006-12-26 The Board Of Trustees Of The University Of Illinois Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US20040091936A1 (en) * 2002-05-24 2004-05-13 Michael West Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank
WO2003106656A2 (en) 2002-06-17 2003-12-24 Thrasos, Inc. Single domain tdf-related compounds and analogs thereof
JP2006514823A (ja) 2002-08-20 2006-05-18 ミレニアム ファーマスーティカルズ インク 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法
AU2003298775B2 (en) 2002-11-26 2008-07-17 Anthrogenesis Corporation Cytotherapeutics, cytotherapeutic units and methods for treatments using them
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
CA2761987A1 (en) 2003-10-07 2005-04-21 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US7951532B2 (en) 2003-11-12 2011-05-31 Children's Hospital Medical Center Method of screening a midkine modulating agent
US7371539B2 (en) 2003-12-03 2008-05-13 President And Fellows Of Harvard College Targeted polypeptide degradation
US7622108B2 (en) 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
JP4971149B2 (ja) 2004-06-17 2012-07-11 スラソス セラピューティックス インコーポレーテッド Ｔｄｆ関連化合物およびその類似体
WO2006012304A2 (en) 2004-06-25 2006-02-02 The Salk Institute For Biological Studies Increasing life span by modulation of smek
US20080184380A1 (en) * 2004-10-22 2008-07-31 Therapeutic Human Polyclonals Inc. Suppression of Endogenous Immunoglobulin Expression in Non-Human Transgenic Animals
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
US20060147429A1 (en) * 2004-12-30 2006-07-06 Paul Diamond Facilitated cellular reconstitution of organs and tissues
US20060148080A1 (en) * 2004-12-30 2006-07-06 Paul Diamond Methods for supporting and producing human cells and tissues in non-human mammal hosts
JP2008536869A (ja) 2005-04-15 2008-09-11 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ Ｋｒｃ活性を調節することによる骨形成および石灰化の調節方法
WO2007030820A2 (en) 2005-09-09 2007-03-15 The Johns Hopkins University Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
CA2623106C (en) 2005-09-19 2013-12-24 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
US8299212B2 (en) 2005-09-20 2012-10-30 Thrasos Therapeutics, Inc. TDF-related compounds and analogs thereof, analogs and bioactive fragments
NZ597304A (en) 2005-10-13 2013-06-28 Anthrogenesis Corp Immunomodulation using placental stem cells
PL2471907T3 (pl) 2005-12-29 2019-07-31 Celularity, Inc. Populacje komórek macierzystych łożyska
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US7875453B2 (en) 2006-06-14 2011-01-25 Bioe Llc Differentiation of multi-lineage progenitor cells to hepatocytes
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
ATE536374T1 (de) 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
US20080188573A1 (en) * 2007-02-02 2008-08-07 Alcon Research, Ltd. Use of thy1-fp transgenic mouse for the identification of ophthalmic agents
NZ612888A (en) 2007-02-12 2015-02-27 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
RU2536242C2 (ru) 2007-09-28 2014-12-20 Антродженезис Корпорейшн Угнетение опухолей с помощью плацентарного перфузата человека и выделенных из плаценты человека вспомогательных натуральных клеток-киллеров
WO2009055656A2 (en) 2007-10-26 2009-04-30 Centocor, Inc. Vectors, host cells, and methods of production and uses
US8101354B2 (en) * 2008-01-15 2012-01-24 University Of Kentucky Research Foundation Method for screening for a tobiano coat color genotype
KR20200011604A (ko) 2008-08-20 2020-02-03 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
RU2015130665A (ru) 2008-11-19 2018-12-24 Антродженезис Корпорейшн Амниотические адгезивные клетки
US9181315B2 (en) 2009-01-08 2015-11-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
EP2261242A1 (en) 2009-06-10 2010-12-15 Universite Catholique De Louvain Aspartate-N-acetyltransferase enzyme, diagnostic method and therapeutic method
CN102686722B (zh) 2009-09-23 2014-11-05 达芬奇生物科技有限责任公司 脐带衬干细胞及其分离和培养方法和材料
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
JP2013520162A (ja) 2010-01-22 2013-06-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 代謝障害の同定、査定、予防および治療のための組成物、キットおよび方法
DK3284818T3 (da) 2010-01-26 2022-06-20 Celularity Inc Behandling af knoglerelateret kræft ved hjælp af placenta stamceller
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
DK2556145T3 (en) 2010-04-07 2016-11-07 Anthrogenesis Corp Angiogenesis using placental stem cells
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
MX342995B (es) 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
ES2707579T3 (es) 2011-06-01 2019-04-04 Celularity Inc Tratamiento del dolor usando citoblastos placentarios
WO2013039996A1 (en) 2011-09-13 2013-03-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
SI2770821T1 (en) 2011-10-28 2018-01-31 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex of mice
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
DK3590332T3 (da) 2011-10-28 2022-05-23 Regeneron Pharma Genmodificerede mus, der eksprimerer kimære major histokompatibilitetskompleks (MHC) II-molekyler
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
JP6400480B2 (ja) 2012-02-15 2018-10-03 ノヴォ ノルディスク アー／エス ペプチドグリカン認識タンパク質１に結合する抗体
SMT201700488T1 (it) 2012-02-15 2017-11-15 Novo Nordisk As Anticorpi che legano e bloccano il recettore d'innesco espresso sulle cellule mieloidi-1 (trem-1)
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
KR102714111B1 (ko) 2013-02-20 2024-10-11 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
PL2958937T3 (pl) 2013-02-22 2019-01-31 Regeneron Pharmaceuticals, Inc. Myszy ekspresjonujące humanizowany główny układ zgodności tkankowej
DK3049521T3 (en) 2013-09-25 2019-04-23 Univ Cornell Compounds for inducing antitumor immunity and methods thereof
CA2935804A1 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
CN113349159B (zh) 2015-04-06 2022-11-11 瑞泽恩制药公司 非人动物中的人源化t细胞介导的免疫应答
EP3368157B1 (en) 2015-10-29 2022-06-29 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
US12006550B2 (en) 2020-10-12 2024-06-11 University Of South Carolina Targeting treatment for ADAM30 in pathological cells
AU2022249328A1 (en) 2021-03-31 2023-09-21 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
WO2025058090A1 (ja) * 2023-09-13 2025-03-20 公益財団法人東京都医学総合研究所 Mhc遺伝子群欠損動物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK105582A (da) * 1982-03-11 1983-09-12 Nordisk Insulinlab Fremgangsmaade til bestemmelse af humane hla-d(r) vaevstyper og gensonde til brug ved fremgangsmaaden

Also Published As

Publication number Publication date
KR920701419A (ko) 1992-08-11
AU6150590A (en) 1991-02-22
EP0950707B1 (en) 2009-02-18
EP0437576A1 (en) 1991-07-24
AU633958B2 (en) 1993-02-11
EP0437576A4 (en) 1992-06-10
ATE423195T1 (de) 2009-03-15
US5416260A (en) 1995-05-16
DE69034263D1 (de) 2009-04-02
NO911164D0 (no) 1991-03-22
EP0437576B1 (en) 2002-07-03
DE69033493D1 (de) 2004-08-12
KR100226158B1 (ko) 1999-10-15
JPH04501510A (ja) 1992-03-19
WO1991001140A1 (en) 1991-02-07
EP0950707A1 (en) 1999-10-20
NO314458B1 (no) 2003-03-24

Similar Documents

Publication Publication Date Title
NO911164L (no) Homolog rekombinasjon for universale donatorceller og chimere pattedyrverter.
DE69434986D1 (de) Homologe rekombination für universelle donorzellen und chimerische säugetierzellen
DK0452484T3 (da) Fremstilling af proteiner ved homolog rekombination
GR3020240T3 (en) Generation of xenogeneic antibodies
DE3851399D1 (de) Transientes Expressionssystem zur Herstellung von rekombinantem Protein.
DE69836092D1 (de) Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
DE69231947D1 (de) Genherstellung zur produktion von transgenfisch
MX164250B (es) Metodo mejorado para producir un vector de expresion de baculovirus recombinante
ATE27000T1 (de) Expression von polypeptiden in hefen.
ATE381614T1 (de) Bildung von xenogenen antikörpern
NO874495D0 (no) Ekspresjon av protein c.
DK139493A (da) Rekombinant plasmid, bakteriekultur transformeret dermed samt kulturens anvendelse
DE3856488D1 (de) Induzierbare Virusresistenz bei Pflanzen
DE69832716D1 (de) Herstellung embryonischer vogel keimzellinien durch verlängerte kultivierung von pgcs, verwendung desselben zur klonierung und chimerisierung
NO862601D0 (no) Ekspresjon av protein c.
ATE148745T1 (de) Kontrolle der mikrosporogenese durch verwendung von externinduzierbaren promotorsequenzen
CA2037907A1 (en) Homologous recombination for universal donor cells and chimeric mammalian hosts
Koller et al. Homologous recombination for universal donor cells and chimeric mammalian hosts
JPS52127244A (en) Manufacture of optical fiber

Legal Events

Date Code Title Description
MK1K Patent expired